Deborah A Greene

US Patent:

20220204941, Jun 30, 2022

Filed:

Mar 15, 2022

Appl. No.:

17/695538

Inventors:

- San Diego CA, US
Deborah Lynn Greene NGUYEN - San Diego CA, US
Lauran MADDEN - San Diego CA, US

International Classification:

C12N 5/071
A61K 35/15
G01N 33/50
A61K 35/38

Abstract:

Disclosed are methods of assessing the ability of a candidate therapeutic agent to reverse, reduce or prevent intestinal injury by a potential toxic agent using a three-dimensional, engineered, bioprinted, biological intestinal tissue model. Also disclosed are methods of assessing the effect of an agent on intestinal function, the method comprising contacting the agent with a three-dimensional, engineered, bioprinted, biological intestinal tissue model.

US Patent:

20220204942, Jun 30, 2022

Filed:

Mar 15, 2022

Appl. No.:

17/695546

Inventors:

- San Diego CA, US
Deborah Lynn Greene NGUYEN - San Diego CA, US
Lauran MADDEN - San Diego CA, US

International Classification:

C12N 5/071
A61K 35/15
G01N 33/50
A61K 35/38

Abstract:

Disclosed are methods of assessing the ability of a candidate therapeutic agent to reverse, reduce or prevent intestinal injury by a potential toxic agent using a three-dimensional, engineered, bioprinted, biological intestinal tissue model. Also disclosed are methods of assessing the effect of an agent on intestinal function, the method comprising contacting the agent with a three-dimensional, engineered, bioprinted, biological intestinal tissue model.

US Patent:

20220195380, Jun 23, 2022

Filed:

Oct 1, 2021

Appl. No.:

17/491862

Inventors:

- San Diego CA, US
Deborah Lynn Greene NGUYEN - San Diego CA, US
Sharon C. PRESNELL - Poway CA, US
Shelby Marie KING - San Diego CA, US

International Classification:

C12N 5/00
C12N 5/071
C12N 5/077
B41J 2/01
B29C 64/112
B33Y 70/00
B33Y 80/00

Abstract:

Disclosed herein are improved methods for fabricating bioprinted, three-dimensional, biological tissues. The methods relate to exposures to low temperatures, incubations at low temperatures of various durations, and fabrication in environments without structural cross-linking treatments.

US Patent:

20210284967, Sep 16, 2021

Filed:

Nov 10, 2017

Appl. No.:

16/349109

Inventors:

- San Diego CA, US
Deborah Lynn Greene NGUYEN - San Diego CA, US
Lauran MADDEN - San Diego CA, US

International Classification:

C12N 5/071
A61K 35/15
G01N 33/50

Abstract:

Disclosed are methods of assessing the ability of a candidate therapeutic agent to reverse, reduce or prevent intestinal injury by a potential toxic agent using a three-dimensional, engineered, bioprinted, biological intestinal tissue model. Also disclosed are methods of assessing the effect of an agent on intestinal function, the method comprising contacting the agent with a three-dimensional, engineered, bioprinted, biological intestinal tissue model.

US Patent:

20200115682, Apr 16, 2020

Filed:

Apr 3, 2018

Appl. No.:

16/500521

Inventors:

Deborah Lynn GREENE NGUYEN - San Diego CA, US
Dwayne E. CARTER - San Diego CA, US
Rhiannon HARDWICK - San Diego CA, US
Alice Chen WALTERS - San Diego CA, US
Sharon C. PRESNELL - Poway CA, US
Chirag B. KHATIWALA - San Diego CA, US
Rami NASRALLAH - San Diego CA, US

International Classification:

C12N 5/071
G01N 33/50
G01N 33/68
G09B 23/30

Abstract:

The invention is directed to three-dimensional, engineered, bioprinted biological tissue constructs exhibiting a liver disorder, methods of making the constructs, and use of the constructs in assays, such as drug testing and molecular diagnostic testing, including methods of assessing the ability of a candidate therapeutic agent to reverse, reduce, or prevent a liver disorder, and methods for biomarker discovery.

US Patent:

20200018747, Jan 16, 2020

Filed:

Sep 28, 2017

Appl. No.:

16/334937

Inventors:

- San Diego CA, US
Deborah Lynn Greene NGUYEN - San Diego CA, US
Sharon C. PRESNELL - San Diego CA, US

Assignee:

Organovo, Inc. - San Diego CA

International Classification:

G01N 33/50
C12N 5/00
C12N 5/071
G01N 33/573

Abstract:

Disclosed are methods of assessing the ability of a candidate therapeutic agent to reverse, reduce or prevent renal injury by a potential toxic agent using a three-dimensional, engineered, bioprinted, biological renal tubule model. Also disclosed are methods of assessing the effect of an agent on renal function, the method comprising contacting the agent with a three-dimensional, engineered, bioprinted, biological renal tubule model. Also disclosed are models of renal disorder. In one embodiment, disclosed are models of renal fibrosis, comprising a three-dimensional, engineered, bioprinted, biological renal tubule model. Also disclosed are methods of making the model of renal disorder. In one embodiment disclosed are methods of making the model of renal fibrosis comprising contacting a three-dimensional, engineered, bioprinted, biological renal tubule model with an agent that is capable of inducing interstitial fibrotic tissue formation.

US Patent:

20190309264, Oct 10, 2019

Filed:

Aug 15, 2017

Appl. No.:

16/325523

Inventors:

- San Diego CA, US
- Portland OR, US
Deborah Lynn Greene NGUYEN - San Diego CA, US
Minji JO - San Diego CA, US
Rosalie Sears PELZ - Portland OR, US
Ellen LANGER - Portland OR, US

International Classification:

C12N 5/071
C12N 5/00
C12N 5/077
C12N 5/09
A01K 67/027
G01N 33/50
A61K 49/00
B33Y 70/00
B33Y 80/00

Abstract:

Described are three-dimensional, engineered, biological cancer models, methods of producing the same, and methods of identifying a therapeutic agent for cancer in an individual utilizing the three-dimensional, engineered, biological cancer models.

US Patent:

20180272035, Sep 27, 2018

Filed:

Nov 5, 2015

Appl. No.:

15/524578

Inventors:

- San Diego CA, US
- Paris, FR
Deborah Lynn Greene Nguyen - San Diego CA, US
Sharon C. Presnell - Poway CA, US
Jessica Langer - Teaneck NJ, US
Guive Balooch - New York NY, US
Elizabeth Wu - San Francisco CA, US
Julien Demaude - Paris, FR

International Classification:

A61L 27/36
A61L 27/60
A61L 27/50
G01N 33/50

Abstract:

Disclosed are bioprinted, three-dimensional, biological skin tissues comprising: a dermal layer comprising dermal fibroblasts; and an epidermal layer comprising keratinocytes, the epidermal layer in contact with the dermal layer to form the three-dimensional, engineered, biological skin tissue. Also disclosed are arrays of engineered skin tissues and methods of making engineered skin tissues.